Patients with higher expression of GAS6 in ovarian tumors failed to respond effectively to neoadjuvant chemotherapy, had poor progression-free survival and overall survival as compared to those with lower GAS6 expression levels. The gene discussed is GAS6; the disease is ovarian neoplasm.